



**DEPARTMENT OF HEALTH & HUMAN
SERVICES**

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21656/S-019

SUPPLEMENT APPROVAL

Abbott Laboratories
Attention: Kelly Kaleck-Schlinsog
Associate Director, Dyslipidemia
200 Abbott Park Road
Abbott Park, IL 60064

Dear Ms. Kaleck-Schlinsog:

Please refer to your Supplemental New Drug Application (sNDA) dated December 17, 2009 received December 18, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tricor (fenofibrate) Tablets, 48 mg, 145 mg.

We acknowledge receipt of your amendments dated January 13 and August 27, 2010.

This supplement provides for revisions to the CLINICAL PHARMACOLOGY section, Drug-Drug Interactions subsection, in response to our letter dated November 25, 2008 regarding bioanalytical analysis that was conducted by [REDACTED] (b) (4). Specifically, the information regarding concomitant administration of fenofibrate with pravastatin was revised, and information on concomitant use with ezetimibe was deleted.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert) and include the labeling changes proposed in any pending "Changes Being Effectuated" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA, to CDERMedWatchSafetyAlerts@fda.hhs.gov, and to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Regulatory Project Manager, at (301) 796-1234.

Sincerely,

{See appended electronic signature page}

Eric Colman, MD
Deputy Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC C COLMAN
10/20/2010